Synthetic Strategies for (−)-Cannabidiol and Its Structural Analogs

Byunghyuck Jung; Jungkyu K. Lee; Jungnam Kim; Eunhye K. Kang; Sang Yeong Han; Hee Yoon Lee; Insung S. Choi

doi:10.1002/asia.201901179

Synthetic Strategies for (−)-Cannabidiol and Its Structural Analogs

Byunghyuck Jung, Jungkyu K. Lee, Jungnam Kim, Eunhye K. Kang, Sang Yeong Han, Hee Yoon Lee, Insung S. Choi

Research output: Contribution to journal › Review article › peer-review

33 Scopus citations

Abstract

(−)-Cannabidiol ((−)-CBD), a non-psychoactive phytocannabinoid from Cannabis, and its structural analogs have received growing attention in recent years because of their potential therapeutic benefits, including neuroprotective, anti-epileptic, anti-inflammatory, anxiolytic, and anti-cancer properties. (−)-CBD and its analogs have been obtained mainly based on extraction from the natural source; however, the conventional extraction-based methods have some drawbacks, such as poor quality control along with purification difficulty. Chemical-synthetic strategies for (−)-CBD could tackle these issues, and, additionally, generate novel (−)-CBD analogs that exhibit advanced biological activities. This review concisely summarizes the historic and recent milestones in the synthetic strategies for (−)-CBD and its analogs.

Original language	English
Pages (from-to)	3749-3762
Number of pages	14
Journal	Chemistry - An Asian Journal
Volume	14
Issue number	21
DOIs	https://doi.org/10.1002/asia.201901179
State	Published - 4 Nov 2019

Keywords

(−)-cannabidiol
cannabidiol analogs
hemp plant
medical marijuana
therapeutic effects

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/asia.201901179

Cite this

@article{5b23f234952446839afe6076adb25abb,

title = "Synthetic Strategies for (−)-Cannabidiol and Its Structural Analogs",

abstract = "(−)-Cannabidiol ((−)-CBD), a non-psychoactive phytocannabinoid from Cannabis, and its structural analogs have received growing attention in recent years because of their potential therapeutic benefits, including neuroprotective, anti-epileptic, anti-inflammatory, anxiolytic, and anti-cancer properties. (−)-CBD and its analogs have been obtained mainly based on extraction from the natural source; however, the conventional extraction-based methods have some drawbacks, such as poor quality control along with purification difficulty. Chemical-synthetic strategies for (−)-CBD could tackle these issues, and, additionally, generate novel (−)-CBD analogs that exhibit advanced biological activities. This review concisely summarizes the historic and recent milestones in the synthetic strategies for (−)-CBD and its analogs.",

keywords = "(−)-cannabidiol, cannabidiol analogs, hemp plant, medical marijuana, therapeutic effects",

author = "Byunghyuck Jung and Lee, {Jungkyu K.} and Jungnam Kim and Kang, {Eunhye K.} and Han, {Sang Yeong} and Lee, {Hee Yoon} and Choi, {Insung S.}",

note = "Publisher Copyright: {\textcopyright} 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim",

year = "2019",

month = nov,

day = "4",

doi = "10.1002/asia.201901179",

language = "English",

volume = "14",

pages = "3749--3762",

journal = "Chemistry - An Asian Journal",

issn = "1861-4728",

publisher = "John Wiley and Sons Ltd",

number = "21",

}

TY - JOUR

T1 - Synthetic Strategies for (−)-Cannabidiol and Its Structural Analogs

AU - Jung, Byunghyuck

AU - Lee, Jungkyu K.

AU - Kim, Jungnam

AU - Kang, Eunhye K.

AU - Han, Sang Yeong

AU - Lee, Hee Yoon

AU - Choi, Insung S.

PY - 2019/11/4

Y1 - 2019/11/4

N2 - (−)-Cannabidiol ((−)-CBD), a non-psychoactive phytocannabinoid from Cannabis, and its structural analogs have received growing attention in recent years because of their potential therapeutic benefits, including neuroprotective, anti-epileptic, anti-inflammatory, anxiolytic, and anti-cancer properties. (−)-CBD and its analogs have been obtained mainly based on extraction from the natural source; however, the conventional extraction-based methods have some drawbacks, such as poor quality control along with purification difficulty. Chemical-synthetic strategies for (−)-CBD could tackle these issues, and, additionally, generate novel (−)-CBD analogs that exhibit advanced biological activities. This review concisely summarizes the historic and recent milestones in the synthetic strategies for (−)-CBD and its analogs.

AB - (−)-Cannabidiol ((−)-CBD), a non-psychoactive phytocannabinoid from Cannabis, and its structural analogs have received growing attention in recent years because of their potential therapeutic benefits, including neuroprotective, anti-epileptic, anti-inflammatory, anxiolytic, and anti-cancer properties. (−)-CBD and its analogs have been obtained mainly based on extraction from the natural source; however, the conventional extraction-based methods have some drawbacks, such as poor quality control along with purification difficulty. Chemical-synthetic strategies for (−)-CBD could tackle these issues, and, additionally, generate novel (−)-CBD analogs that exhibit advanced biological activities. This review concisely summarizes the historic and recent milestones in the synthetic strategies for (−)-CBD and its analogs.

KW - (−)-cannabidiol

KW - cannabidiol analogs

KW - hemp plant

KW - medical marijuana

KW - therapeutic effects

UR - http://www.scopus.com/inward/record.url?scp=85074348862&partnerID=8YFLogxK

U2 - 10.1002/asia.201901179

DO - 10.1002/asia.201901179

M3 - Review article

C2 - 31529613

AN - SCOPUS:85074348862

SN - 1861-4728

VL - 14

SP - 3749

EP - 3762

JO - Chemistry - An Asian Journal

JF - Chemistry - An Asian Journal

IS - 21

ER -

Synthetic Strategies for (−)-Cannabidiol and Its Structural Analogs

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this